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Abstract: We live and to do so we must breathe and eat, so are we a combination of what we eat and 12 
breathe? Here we will consider this question, and the role in this respect of the AMP-activated protein 13 
kinase (AMPK). Emerging evidence suggests that AMPK facilitates central and peripheral reflexes 14 
that coordinate breathing and oxygen supply, and contributes to central regulation of feeding and 15 
food choice. We propose, therefore, that oxygen supply to the body is aligned with not only the 16 
quantity we eat, but also nutrient-based diet selection, and that the cell-specific expression pattern of 17 
AMPK subunit isoforms is critical to appropriate system alignment in this respect. Currently 18 
available information on how oxygen supply may be aligned with feeding and food choice, or vice 19 
versa, through our motivation to breathe and select particular nutrients is sparse, fragmented and 20 
lacks any integrated understanding. By addressing this, we aim to provide the foundations for a 21 
clinical perspective that reveals untapped potential, by highlighting how aberrant cell-specific 22 
changes in the expression of AMPK subunit isoforms could give rise, in part, to known associations 23 
between metabolic disease, such as obesity and type 2 diabetes, sleep-disordered breathing, 24 
pulmonary hypertension and acute respiratory distress syndrome. 25 
Key words: AMPK, LKB1, hypoxia, altitude, Hypoxic ventilatory response, hypoxic pulmonary 26 
vasoconstriction, feeding, food choice, thermogenesis, mitochondria, KV1.5, Kv2.1, seep-disordered 27 
breathing, pulmonary hypertension, acute respiratory distress syndrome, obesity, type 2 diabetes, 28 
COVID-19. 29 
1. Introduction 30 
It is evident that we must breathe without serious interruption from birth to death, and we do 31 
so with such ease that it almost goes unnoticed, whether we cough, sneeze, snort, or, from our 32 
partners perspective, snore. That is until the onset of certain respiratory diseases, such as sleep-33 
disordered breathing and pulmonary hypertension. These disorders may appear unrelated to each 34 
other and to be far removed from food choice and metabolic disease, but evidence of cross-35 
associations is growing.  36 
Breathing is coordinated by a sophisticated motor program, which develops in utero in order to 37 
coordinate lung ventilation after birth, and responds appropriately to changes in oxygen demand 38 
during such activities as exercise, sleep or ascent to altitude. The fundamental rhythmic patterns of 39 
ventilatory activity are coordinated by a respiratory central pattern generator (rCPG) through 40 
downstream motor outputs from the brainstem and spinal cord, in a similar way to any other type of 41 
locomotion or rhythmic behavior [1]. This occurs independently of peripheral or higher 42 
(suprapontine) input, with every breath triggered by cyclical phases of inspiratory muscle contraction 43 
(diaphragm, external intercostals), and followed by passive expiration through relaxation of these 44 
muscles. In addition, active expiration may be engaged to increase ventilation through recruitment 45 
of expiratory muscles (the abdominals and internal intercostals) when the rate of metabolism requires 46 
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more oxygen. Alternatively, at the end of inspiration, the process of post-inspiration may adapt to 47 
reduced requirements by lengthening contraction of the diaphragm and adduction of laryngeal 48 
muscles to slow expiratory airflow by increasing airway resistance. These are the principal 49 
components of normal breathing (eupnoea), during which the composition and phasic pattern of 50 
muscle recruitment/activity is state-dependent. Each component of this cycle is built into the rCPG, 51 
central to the activity of which is the pre-Botzinger Complex [2], a brainstem microcircuit from which 52 
the rhythm of inspiration originates. In the present context it is important to note that breathing 53 
patterns exhibit acute adaptation when, for example, metabolism increases, and also adapts on longer 54 
timescales during growth and maturation, pregnancy, ageing, disease and injury.  55 
Perhaps most important of all is our ability to adapt to deficits in oxygen supply, the most vital 56 
elixir of life. This is evident from birth, when hypoxia triggers the first breath due, in part, to the 57 
hypoxic ventilatory response (HVR; Fig. 1). This response increases ventilatory drive through rCPG 58 
and thus triggers subsequent adaptation to extrauterine life, through maturation of the carotid 59 
bodies, our primary peripheral chemoreceptors that drive HVR [3-5], and the airways, alveoli and 60 
pulmonary vasculature of the lungs that enable optimal gaseous exchange [6]. Gaseous exchange at 61 
our lungs is aided by another reflex response to falls in alveolar oxygen availability [7], namely 62 
hypoxic pulmonary vasoconstriction (HPV; Fig. 1). HPV is a local response mediated by mechanisms 63 
intrinsic to the smooth muscles and endothelia of the pulmonary blood vessels, that aids ventilation-64 
perfusion matching, by diverting blood flow through the path of least resistance, from oxygen-65 
deprived to oxygen-rich areas of the lung. By contrast, systemic arteries dilate in response to hypoxia 66 
in order to meet the metabolic needs of the tissues they supply [8,9].  67 
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Figure 1. Turn the AMP up to 11 and breathe. Schematic shows the mechanism by which increases 69 
in the cellular AMP:ATP and ADP:ATP ratios may activate up to 12 AMPK heterotrimeric subunit 70 
combinations, leading to target phosphorylation and induction of the hypoxic ventilatory response 71 
(HVR) and hypoxic pulmonary vasoconstriction (HPV). 72 
The mechanisms of hypoxia-response coupling in those specialised cells that coordinate 73 
cardiorespiratory reflex responses to falls in oxygen availability remain keenly debated topics, 74 
nowhere more so than with respect to HVR and HPV. However, emerging evidence now strongly 75 
suggests that the AMP-activated protein kinase (AMPK) might facilitate both HVR and HPV [10]. 76 
This hypothesis [11,12] was built on prior observations that mitochondria of oxygen-sensing cells 77 
were exquisitely sensitive to hypoxia, and the proposal that this was due to the selective expression 78 
in these cells of a form of cytochrome C oxidase (COX) that was uniquely sensitive to changing PO2 79 
within the physiological range [13,14]. Support for this has been provided not only by the use of 80 
mitochondrial inhibitors [15-20], but by gene deletion strategies that examined the role of two nuclear 81 
encoded atypical subunits of the mitochondrial electron transport chain: (i) NDUFA4L2 encoding 82 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 4-like 2 (NDUFA4L2) [21]; and (ii) COX4I2 83 
encoding cytochrome c oxidase subunit 4 isoform 2 (COX4I2) [22,23]. NDUFA4L2 is a subunit of 84 
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complex I, which transfers electrons from NADH to ubiquinone, while COX4I2 is a subunit of 85 
cytochrome c oxidase, which catalyses the transfer of electrons from cytochrome c to oxygen. 86 
NDUFA4L2 and COX4I2 are constitutively expressed under normoxia not only by oxygen-sensing 87 
type I cells of the carotid body [24], but also by pulmonary arterial myocytes [25,26]. In most other 88 
cell types NDUFA4L2 and COX4I2 expression is ordinarily low, although their expression may be 89 
increased during prolonged hypoxia [22,23]. Accordingly, carotid body type I cell responsiveness to 90 
acute hypoxia and acute HVR are abolished in mice by conditional deletion of Cox4I2 in tyrosine 91 
hydroxylase expressing catecholaminergic cells [27], while HPV is occluded in isolated, ventilated 92 
and perfused lungs from Cox4I2 knockout mice [28]. Therefore, these atypical nuclear encoded 93 
subunits not only represent a further distinguishing feature of oxygen-sensing cells, but, at least in 94 
the case of COX4I2, appear to be critically important for hypoxia-response coupling within the 95 
physiological range of PO2. 96 
Modulation of the properties of COX by COX4I2 is likely critical to hypoxia-response coupling 97 
in these highly specialised cells, because COX4I2 lowers the oxygen affinity of COX [29] and removes 98 
the inhibition by ATP that is normally conferred by COX4I1 [23,30]. In oxygen-sensing cells, 99 
therefore, COX4I2 expression may facilitate rapid decreases in ATP production as oxygen availability 100 
falls within the physiological range (~100 mmHg to ~20 mmHg) [31], in part because the rate of 101 
mitochondrial oxidative phosphorylation will not increase as ATP levels decline [22,25,30,32]. 102 
COX4I2 may thus accelerate increases in ADP:ATP ratios, which would in turn increase AMP:ATP 103 
ratios via the adenylate kinase reaction [33,34], leading ultimately to concomitant activation of AMPK 104 
[35,36].  105 
Also consistent with this, all agents that inhibit mitochondrial oxidative phosphorylation 106 
activate AMPK in an AMP-dependent manner [35,36]. Moreover, there is now a growing realisation 107 
that AMPK is capable of phosphorylating targets outside of those canonical pathways by which it 108 
regulates cell-autonomous metabolic homeostasis [37-46]. In this way it appears that, during 109 
evolution, the role of AMPK in regulating metabolic homeostasis has been extended through natural 110 
selection to support system-level control of substrate supply (e.g. of oxygen, glucose and fatty acids) 111 
in order to maintain energy (ATP) homeostasis across the whole body [11]. 112 
2. The AMP-activated protein kinase and cellular metabolic homeostasis 113 
AMPK is a cellular energy sensor that was originally thought to maintain energy homeostasis in 114 
a cell autonomous manner. It exists as heterotrimers comprising one of two catalytic α subunits, in 115 
combination with one each of the two β and three g regulatory subunits; together these may form at 116 
least 12 different heterotrimeric subunit combinations (Fig. 1) [47]. Evidence is now emerging to 117 
suggest that different subunit combinations are expressed in different cell types, and that each 118 
combination may exhibit differential sensitivities to activation by AMP and ADP and thus metabolic 119 
stresses [48], and may selectively phosphorylate and regulate a different spectrum of target proteins 120 
due to differing subcellular locations [49,50].  121 
There are four potential nucleotide binding sites formed by the CBS repeats on the γ subunit, 122 
although only the CBS1, CBS3 and CBS4 sites may actually be utilised [51,52]. Binding of AMP to the 123 
CBS3 site causes a 10-fold increase in AMPK activity by allosteric activation, and also promotes 124 
further activation of up to 100-fold by promoting phosphorylation, and inhibiting 125 
dephosphorylation, at Thr172 within the activation loop of the α subunit; all of these effects are 126 
opposed by ATP binding [53,54]. Binding of ADP may also mimic the effects of AMP on Thr172 127 
phosphorylation [55] and dephosphorylation [56], although allosteric action is only triggered by 128 
AMP. Thr172 is primarily phosphorylated by the tumour suppressor kinase LKB1, which appears to 129 
be constitutively active [57] but phosphorylates AMPK more rapidly when AMP or ADP is bound to 130 
the γ subunit. There is also an alternative mechanism involving the calmodulin-dependent protein 131 
kinase CaMKK2 [58,59], which phosphorylates Thr172 and thus activates AMPK in a Ca2+-dependent, 132 
AMP-independent manner [47,60-62]. Contrary to previous proposals [63,64], more recent evidence 133 
supports the view that AMPK is not directly activated by reactive oxygen species (ROS), although 134 
ROS can activate AMPK indirectly by inhibiting mitochondrial oxidative phosphorylation and 135 
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increasing cellular AMP:ATP and ADP:ATP ratios [35,36]. Once activated, the classical action of 136 
AMPK is to phosphorylate targets that switch off non-essential anabolic processes that consume ATP 137 
and switch on catabolic pathways that generate ATP [62,65], thereby compensating for deficits in 138 
ATP supply via, for example, reductions in mitochondrial oxidative-phosphorylation.  139 
3. Phosphorylation by AMPK of non-metabolic targets that modulate physiological systems 140 
It is becoming evident that AMPK also phosphorylates and thus modulates a variety of targets 141 
that fall outside of its originally proposed role in the maintenance of metabolic homeostasis [10,11,66-142 
68]. For example, AMPK not only phosphorylates and thus inactivates the pore-forming α subunits of 143 
multiple Ca2+-activated potassium channels (KCa1.1 and KCa3.1) [45,69], the voltage-gated potassium 144 
channel KV1.5 [37-39] and the ATP-inhibited KATP channel (Kir6.2) [70], but also phosphorylates and 145 
activates the α subunit of the voltage-gated potassium channel Kv2.1 [46]. Evidence is also now 146 
emerging that AMPK may directly phosphorylate and regulate: (i) enzymes involved in the 147 
biosynthesis of specific transmitters [40-42]; (ii) receptors for neurotransmitters [43]; and (3) pumps 148 
and transporters [44,71]. In short, its downstream targets provide the necessary “toolkit” via which 149 
AMPK may modulate whole body energy homeostasis, through central control of system-specific 150 
outputs [11] that may coordinate breathing, feeding and, for that matter, food choice. 151 
4. AMPK aids HPV and thus gaseous exchange at the lungs   152 
Investigations into the role of AMPK in oxygen supply began with consideration of its role in 153 
HPV [12,72]. HPV is triggered by airway and/or alveolar hypoxia [7] rather than by vascular 154 
hypoxaemia [73]. HPV occurs through the constriction of pre-capillary resistance arteries within the 155 
pulmonary circulation, in a manner coordinated by signalling pathways that are intrinsic to their 156 
smooth muscles and endothelial cells [74-77], independently of blood-borne mediators or the 157 
autonomic nervous system [78,79]. The initiation phase of acute HPV is primarily driven by smooth 158 
muscle constriction [74], with a threshold PO2 ≈80 mmHg [80]. In addition to COX4I2 expression, 159 
AMPK-a1 levels are markedly higher in pulmonary compared to systemic arterial smooth muscles 160 
[72]. These factors may contribute to the cell-specific engineering that provides for pulmonary 161 
vascular constriction in response to hypoxia and thus ventilation-perfusion matching, rather than 162 
arterial dilation in response to hypoxia by which the systemic vasculature ensures that oxygen 163 
availability meets the needs of the organs and tissues supplied by those vessels [8]. In an evolutionary 164 
context, it is intriguing to note that the lungs represent a relatively late adaptation [81-83], the 165 
transition to which is still evident in the metamorphosis of gill-breathing tadpoles to lung-assisted, 166 
air-breathing adult amphibians [84]. 167 
Exposure of pulmonary arterial smooth muscles to physiological hypoxia increases cellular 168 
AMP:ATP and ADP:ATP ratios, leading to concomitant AMPK activation and consequent 169 
phosphorylation of acetyl-CoA carboxylase (ACC; a well-validated marker for AMPK activation) 170 
[72]. Accordingly, relatively mild mitochondrial inhibition using the biguanide phenformin [85,86], 171 
like hypoxia,  increased cellular NAD(P)H auto-fluorescence, activated AMPK and increased ACC 172 
phosphorylation [72]. By contrast AICA riboside, which is taken up into cells and metabolised to the 173 
AMP mimetic ZMP (AICA riboside monophosphate) [87], activated AMPK and increased ACC 174 
phosphorylation without affecting NAD(P)H auto-fluorescence  [72].   175 
Critically, AMPK activation by AICA riboside evoked a slow, sustained and reversible 176 
constriction of pulmonary artery rings, with strikingly similar characteristics when compared to the 177 
sustained phase of HPV, namely: (1) a requirement for smooth muscle SR Ca2+ release via ryanodine 178 
receptors that is retained, albeit attenuated, after removal of extracellular Ca2+; (2) Ca2+ influx into and 179 
vasoconstrictor release from the pulmonary artery endothelium [72]. Consistent with these findings, 180 
HPV was also inhibited by the non-selective AMPK antagonist compound C [88]. However, any 181 
action of this agent should be considered with caution, because in a screen of 70 protein kinases it 182 
was shown to inhibit several other kinases more potently than AMPK [89].  183 
In pulmonary arterial smooth muscles, the first functionally relevant and hypoxia-responsive 184 
molecular target to be identified downstream of mitochondria was the voltage-gated ion channel 185 
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KV1.5, which is rapidly and reversibly inhibited by hypoxia [16,90,91]. The precise role of KV1.5 186 
inhibition in acute HPV remains open to debate. Nevertheless, it provides a well-defined molecular 187 
target, the regulation of which by AMPK has been explored using new and more selective small 188 
molecule activators of AMPK, namely A769662 [92,93] and Compound 13 [94]. Each of these agents 189 
triggered AMPK-dependent phosphorylation of recombinant KV1.5 channel a subunits and inhibited 190 
potassium currents carried by these channels when expressed in HEK293 cells, while recombinant 191 
activated human AMPK phosphorylated KV1.5 a subunits in cell-free assays, at serine residues S559 192 
and S592 [39,50].  A non-phosphorylatable KV1.5 mutation (S559A) virtually abolished inhibition by 193 
Compound 13 of KV1.5 currents, albeit with a modest impact on overall phosphorylation. By contrast, 194 
an S592A mutation reduced phosphorylation to a larger extent, but only partially blocked current 195 
inhibition, perhaps indicating cooperativity of function between S559 and S592 [50]. More 196 
significantly still, A769662 and Compound 13 not only inhibited KV currents in acutely isolated 197 
pulmonary arterial smooth muscle cells, but occluded further inhibition of these potassium currents 198 
by hypoxia and inhibitors of mitochondrial oxidative phosphorylation [39]. Consistent with the 199 
action of compound 13, which is an AMPK-a1-selective agonist [94], conditional deletion of AMPK-200 
a1, but not AMPK-a2, in smooth muscles almost abolished inhibition of KV1.5 channel currents in 201 
pulmonary arterial myocytes by hypoxia and mitochondrial inhibitors [50]. By contrast, however, 202 
intracellular dialysis of AMPK heterotrimers containing either AMPK-α1 or AMPK-α2 inhibited 203 
KV1.5 in rat pulmonary arterial myocytes [39], adding further weight to the argument that target 204 
specificity is determined by the anchoring of endogenous AMPK heterotrimers proximal to their 205 
targets, rather than by the intrinsic target specificity of any given subunit combination. The AMPK 206 
isoforms used in these latter studies were bacterially expressed α1β2g1 or α2β2g1 complexes that had 207 
been irreversibly activated by thiophosphorylation of Thr172 (thiophosphorylated serine/threonine 208 
residues are completely resistant to dephosphorylation) while the controls had mutations in their 209 
kinase domain that abolished kinase activity [45]. 210 
Conclusive evidence of a role for the LKB1-AMPK signalling pathways in HPV in vivo was then 211 
provided by gene deletion strategies in combination with spectral Doppler ultrasound, which 212 
demonstrated that HPV is markedly attenuated by global knockdown of the gene encoding LKB1 213 
(Stk11), and virtually abolished by conditional deletion of AMPK-a1 in smooth muscles [50]. By 214 
contrast HPV remained unaffected in mice with global CaMKK2 deletion [50]. As yet, however, the 215 
precise mechanisms by which AMPK mediates SR calcium release through ryanodine receptors of 216 
pulmonary arterial myocytes remains to be determined, while the proposed requirement for 217 
endothelial AMPK in acute HPV has yet to be confirmed. 218 
Adding to this it is evident that divergent LKB1-AMPK signalling pathways might coordinate 219 
HPV and pulmonary vascular metabolism downstream of mitochondria. Thus, deletion in smooth 220 
muscles of AMPK-α1, but not AMPK-α2, blocked the induction of HPV during mild hypoxia, 221 
indicating that there is no redundancy of function in this respect between AMPK catalytic subunit 222 
isoforms. By contrast, deletion of AMPK-α1 and AMPK-α2, respectively, attenuated HPV during 223 
exposure of mice to severe alveolar hypoxia. This indicates, perhaps, that AMPK-α2-containing 224 
heterotrimers are required in some specific way to coordinate ATP supply in support of HPV, rather 225 
than to regulate smooth muscle constriction per se.  226 
The finding that AMPK-α1 is critical to both KV1.5 inhibition and HPV is all the more intriguing, 227 
given that SNPs in the PRKAA1 gene (encoding AMPK-a1) have been identified in native Andean 228 
populations that live at, and are adapted to high altitude [95], and exhibit attenuated HPV [96]. 229 
5. AMPK and central neural control mechanisms 230 
By acting centrally, AMPK may contribute yet wider system-specific control by influencing 231 
neural circuit mechanisms that serve to balance breathing, energy intake and energy expenditure. As 232 
mentioned above and exemplified by our studies on HPV, AMPK may achieve this via cell-specific 233 
expression not only of different AMPK subunit isoforms, but also of unique sets of receptors for 234 
hormones and neurotransmitters, and ion channels. In this way AMPK may confer, according to 235 
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location, system-specific differences in sensitivities to metabolic stresses, such as oxygen or glucose 236 
deprivation, or to hormones and neurotransmitters that activate AMPK via the CaMKK2 pathway.  237 
One way in which AMPK may regulate central neural control mechanisms is illustrated by our 238 
most detailed study on the regulation by AMPK of another ion channel, namely KV2.1. Similar to 239 
KV1.5, AMPK phosphorylates KV2.1 in cell-free assays and in intact cells at two sites (Ser440 and 240 
Ser537) within the C-terminal cytoplasmic tail [46]. In HEK-293 cells stably expressing KV2.1, AMPK 241 
activation using A-769662 caused hyperpolarising shifts in the current–voltage relationship for 242 
channel activation and inactivation, which were almost abolished by single (S440A) and completely 243 
abolished by double (S440A/S537A) phosphorylation-resistant mutations. In cells expressing wild 244 
type KV2.1, channel activation was also observed upon the intracellular administration of activated, 245 
thiophosphorylated AMPK (α2β2g1), but not an inactive control [46]. KV2.1 is a voltage-gated, 246 
delayed rectifier potassium channel. Because of its relatively slow opening and closing in response 247 
to depolarisation, it is not thought to be involved in repolarising neurons after single action 248 
potentials, but instead to contribute to adjustments in the firing frequency of action potentials by 249 
raising the threshold membrane potential that must be reached between successive activations of the 250 
voltage-gated Na+ channels that determine action potential frequency. Accordingly, treatment of 251 
primary rat hippocampal neurons in culture with A-769662 caused hyperpolarising shifts in gating 252 
qualitatively similar to those observed in HEK-293 cells expressing KV2.1. That this effect was 253 
mediated by KV2.1 was indicated by its abolishen when an anti-KV2.1 antibody was applied 254 
intracellularly via the patch pipette. Moreover, intracellular administration of active, 255 
thiophosphorylated α2β2g1 complexes reduced the firing of action potentials in the neurons as 256 
predicted, whereas inactive control complexes had no effect (Fig. 2). Therefore, AMPK not only 257 
regulates metabolic homeostasis of neurons, but also neuronal firing frequency.  258 
Kv2.1 is widely expressed in the central nervous system, particularly in pyramidal neurons in 259 
the hippocampus and cortex [97]. By contrast, the expression of Kv1.5, which is inhibited rather than 260 
activated by AMPK [39,50], appears to be restricted to the caudate putamen, the granule layer of the 261 
cerebellum, trigeminal sensory ganglia, pituitary gland and olfactory system (olfactory bulb, 262 
trigeminal terminal nerves and nasal vomeronasal organ) [98-100]. This highlights well the capacity 263 
for cell- and system-specific modulation of neural circuit mechanisms by AMPK. 264 
 265 
 266 
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Figure 2. When the clock strikes twelve well cool off then. Active or inactive complexes of AMPK 267 
were applied intracellularly by dialysis from a patch pipette, and recordings taken at 0min and 10 268 
minutes after entering the whole-cell configuration. Action potentials were triggered by current 269 
injection. Redrawn from [101]. 270 
 271 
The firing of action potentials, together with downstream postsynaptic events, are estimated to 272 
account for up to 80% of all energy turnover in the grey matter of rodent brain [102]. Since KV2.1 is 273 
widely expressed, its activation by AMPK could be a cell-autonomous mechanism to conserve energy 274 
by reducing membrane excitability and firing of action potentials in response to energy stress. It is 275 
interesting to speculate that this mechanism might also contribute during sleep, when breathing 276 
slows and central energy reserves are replenished. Indeed, knockdown of AMPK in the central 277 
nervous system of the fruit fly Drosophila melanogaster led to disturbances in sleep patterns and to 278 
poorer recovery from sleep deprivation [103].  279 
During drowsiness and light non-rapid eye movement sleep a moderate decrease in the 280 
oscillating breathing pattern occurs, with significant variation in periodicity of ventilation due, in 281 
part, to instability of central respiratory drive and blunted HVR. By contrast, in deep non-rapid eye 282 
movement sleep the pattern of breathing is more regular, although the tendency to hypoventilate 283 
increases. This hypoventilation seems to be the result of both decreased ventilatory drive and 284 
increased upper airway resistance. Rapid eye movement (REM) sleep is characterised by more 285 
irregular and yet shallower breathing, synchronous with REM bursts [104]. During the sleep cycle, 286 
the carotid bodies and downstream chemo-responsive respiratory networks of the brain continue to 287 
monitor oxygen and carbon dioxide levels, and coordinate appropriate adjustments to breathing, 288 
sympathetic tone and blood pressure. Periodic hypoxia and hypercapnia may result from brief 289 
periods of breathing cessation (apnoea), which occur in normal subjects during sleep, but become 290 
more frequent and prolonged in patients suffering from sleep-disordered breathing, due either to 291 
obstruction of the upper airway (obstructive sleep apnoea) or defective respiratory rhythm 292 
generation by the central nervous system (central sleep apnoea). Apnoea leads to increased 293 
respiratory drive through activation of chemosensory networks, and subsequent arousal from sleep 294 
[105-107]. 295 
This brings us neatly to cell- and circuit-specific functions of the nervous system through which 296 
AMPK may contribute to the regulation of breathing, energy supply and energy expenditure during 297 
wakefulness. 298 
6. AMPK, HVR and oxygen supply 299 
As mentioned previously, AMPK is intimately coupled to mitochondrial metabolism through 300 
sensing of cellular AMP:ATP and ADP:ATP ratios, and mitochondria of oxygen-sensing cells appear 301 
to be uniquely sensitive to changes in oxygen supply because of their cell-specific expression of two 302 
nuclear-encoded, atypical subunits of the mitochondrial electron transport chain, NDUFA4L2 [21] 303 
and COX4I2 [22,29,108]. Of these, gene deletion strategies have confirmed that COX4I2 is critical to 304 
the activation of both oxygen-sensing carotid body type I cells and acute HVR [27]. 305 
Consistent with a role for AMPK downstream of mitochondria, HVR is markedly attenuated by 306 
conditional deletion of LKB1 [109] or AMPK-α1, and more severely still by dual deletion of both 307 
AMPK-α1 and -α2, using Cre recombinase expression from the tyrosine hydroxylase promoter [110]. 308 
In fact, exposure of these mice to hypoxia triggers hypo-ventilation and apnoea, rather than hyper-309 
ventilation as in the wild type [109,110]. Note that catecholaminergic cells expressing tyrosine 310 
hydroxylase span the entire hypoxia-responsive respiratory network, including therein type I cells of 311 
carotid bodies and brainstem neurons that lie downstream.  312 
The primary peripheral arterial chemoreceptors of mammals are the carotid bodies [111], of 313 
which type I cells represent the archetypal oxygen-sensing cells [112]. The general consensus has been 314 
that it is the afferent input responses of carotid bodies that deliver the entire ventilatory response to 315 
falls in arterial PO2 [5,113]. Challenging this, however, AMPK deletion attenuated HVR during mild 316 
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and severe hypoxia without affecting these afferent input responses. This is consistent with findings 317 
that two compounds that activate AMPK via different mechanisms, i.e. AICA riboside [87] and A-318 
769662 [92,93], do not precisely mimic the effects of hypoxia or induce pronounced activation of 319 
carotid body type I cells [114]. Thus, peripheral chemosensors may not be the sole arbiters of HVR. 320 
This has also been suggested by investigations on the evolution of ventilatory control systems. 321 
Intriguingly, oxygen-sensing and a component of HVR occurs at the level of the caudal brainstem in 322 
amphibians, in which both the location and influence of the primary peripheral chemosensors 323 
changes during metamorphosis from gill-breathing tadpole to lung-assisted, air-breathing adult [84]. 324 
It was proposed [115], therefore, that evolution periodically led to the reconfiguration of peripheral 325 
chemoreceptor inputs [84] about a common, ancestral sensor of hypoxia within the caudal brainstem 326 
(Fig. 3), which effects signal integration and thus acts as the gatekeeper of respiratory adjustments 327 
during hypoxia. In short, HVR may be determined by the coordinated action of the carotid body and 328 
a wider hypoxia-responsive circuit within the brainstem [110,115-117]. 329 
 330 
Figure 3. One, two, three O'clock, four O'clock breathe. Schematic describing the new hypothesis on 331 
the regulation by AMPK of the hypoxic ventilatory response, through integration of local and applied 332 
metabolic stresses. AP = area postrema; NTS = nucleus tractus solitarius. From [110]. 333 
Until recently, little emphasis has been placed on the role of hypoxia-sensing by the brainstem, 334 
perhaps because HVR is so effectively abolished by resection of the carotid sinus nerve in humans 335 
[118]. However, brainstem hypoxia induces HVR even when the brain is in receipt of normoxic 336 
carotid body afferent inputs [119], and does so by directly activating subsets of catecholaminergic 337 
neurons within the nucleus tractus solitarius (NTS) and rostral ventrolateral medulla (RVLM), that 338 
may support partial recovery of HVR in a variety of animal models [116]. Consistent with the effect 339 
of AMPK deletion on HVR, dysfunction of these catecholaminergic neurons precipitates 340 
hypoventilation and apnoea associated with Rett syndrome, which is exacerbated during hypoxia 341 
[120]. Moreover, it is evident that COX4I2 may, as in carotid body type I cells, be constitutively 342 
expressed by certain CNS neurons [30], rendering mitochondrial oxidative phosphorylation sensitive 343 
to falls in local PO2 within the physiological range. AMPK activation could thus be triggered in a 344 
specialised subset of brainstem neurons during hypoxia, to support the delivery of increased 345 
respiratory drive required to protect against hypoventilation and apnoea. Supporting this, 346 
examination of brainstem function in AMPK-a1/a2 knockout mice by functional magnetic resonance 347 
imaging identified reduced activation of discrete dorsal and ventral nuclei of the caudal brainstem, 348 
despite the fact that carotid body afferent input responses were retained [110].  The location of the 349 
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dorsal nucleus aligns with areas of the NTS that are activated during hypoxia and represent the 350 
primary site of receipt of carotid body afferent inputs [116], and is therefore well placed for signal 351 
integration. Here AMPK deletion may attenuate activation during hypoxia of A2 (noradrenergic / 352 
dopaminergic) neurons proximal to the midline and the area postrema [110,121]. Notably, A2 353 
neurons provide afferent inputs to and determine, together with the carotid body, activation by 354 
hypoxia of A1/C1 neurons within the RVLM [122] and the rCPG  [1,123], the position of which aligns 355 
well with the ventral active region identified by fMRI analysis [110]. Through these projections of the 356 
NTS, AMPK could thus support HVR [10,115] by either direct or indirect modulation of the rCPG  357 
[1,123], and perhaps by also aid the coordination of functional hyperaemia [124].  358 
Carotid body afferent discharge of AMPK knockout mice remains exquisitely sensitive to falls 359 
in PO2, and ventilatory responses to hypercapnia remain unaffected even during severe hypoxia. It 360 
is therefore unlikely that AMPK deficiency compromises the capacity during hypoxia either for 361 
activation of the peripheral carotid body type I cells or the brainstem catecholaminergic neurons that 362 
govern the ventilatory response to hypercapnia, exocytosis or effective delivery of increased 363 
respiratory drive [115]. Therefore, the mechanism by which AMPK supports HVR is most likely 364 
neurogenic and highly localised, since AMPK deficiency in smooth muscles does not affect HVR or 365 
systemic arterial blood pressure regulation during hypoxia, while the latter (but not HVR) remains 366 
unaltered following AMPK deletion in catecholaminergic neurons [125]. This presents us with 367 
another example of cell- and system-specific actions of AMPK. 368 
Accepting the possibility of a role in signal integration at the NTS, the working hypothesis is 369 
that AMPK activation by the canonical, AMP/ADP-dependent pathway may provide the capacity for 370 
sensing local hypoxic stress and integrate this with afferent input responses. It seems plausible that 371 
within these specialised NTS neurons, AMPK could very effectively integrate decreased ATP supply 372 
due to local hypoxia with increased ATP usage consequent to afferent inputs from peripheral 373 
chemoreceptors. The firing frequency of action potentials within these NTS neurons could thus be 374 
modulated by AMPK in a manner proportional to the overall ATP demand in the receiving, activated 375 
neurons [10,115]. Neuronal energy supply and activity across the entire circuit, from NTS to rCPG, 376 
may in turn be supported by direct activation during hypoxia of lactate and/or ATP release from 377 
astrocytes throughout the NTS, RVLM and rCPG [117,126-128], to which AMPK may also contribute 378 
by balancing neuronal TCA cycle dynamics [129]. In this respect it is notable that astrocytes also 379 
express COX4I2 [30], because this atypical subunit of the mitochondrial electron transport chain may 380 
not only confer acute sensitivity to physiological hypoxia, but also reduce the capacity for ATP supply 381 
via the TCA cycle in those cells that express it [29].   382 
7. The role of hypothalamic AMPK in regulating appetite and feeding behaviour 383 
Among the most well-established roles of AMPK in the nervous system is in the regulation of 384 
appetite and food intake, which highlights further system-specific functions (Fig. 4). Feeding is 385 
known to be promoted by stimulation of neurons located in the arcuate nucleus of the hypothalamus 386 
that express agouti-related protein (AGRP) and neuropeptide Y (NPY), and to be inhibited by 387 
neurons in the same anatomical location that express pro-opiomelanocortin (POMC) and cocaine-388 
and-amphetamine-regulated transcript (CART). NPY/AgRP neurons increase food intake and 389 
decrease energy expenditure by antagonising POMC action on melanocortin receptors in neurons of 390 
the paraventricular nucleus (PVN). First indications of a role for AMPK in feeding behavior came 391 
from findings that indicated it was activated in rat hypothalamus by treatment in vivo with the 392 
orexigenic hormone ghrelin, and inhibited by treatment with the anorexigenic hormone leptin [130]. 393 
Other orexigenic mediators, such as cannabinoids, were subsequently found to also activate AMPK 394 
[131]. Moreover, injection of the AMPK activator AICA riboside into the hypothalamus led to 395 
increases in food intake [130]. Although AICA riboside is now known to have many “off-target” 396 
(AMPK-independent) effects, the conclusion that its effects on feeding were AMPK-mediated was 397 
strengthened by findings that ectopic expression in mouse hypothalamus of inactive mutants of 398 
AMPK-α1 and -α2 (which lack kinase activity, but exert a dominant negative effect by competing 399 
with endogenous α subunits for binding to β and g subunits) repressed food intake and body weight 400 
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gain. Conversely, expression of an activated g1 mutant (which behaves as if AMP is bound even when 401 
it is not) had the opposite effects. Moreover, leptin was found to decrease the activity of AMPK 402 
complexes containing α2, but not α1, in the hypothalamus [132]. The phenotypes of knocking out 403 
AMPK-α2 in AGRP/NPY and POMC/CART neurons, respectively, were also initially consistent with 404 
a role for AMPK in appetite control, with the former being lean while the latter were obese. However, 405 
in both cases the effects were rather modest and age-dependent, and there were no detectable changes 406 
in food intake in the AGRP/NPY knockouts, while the POMC/CART knockouts still responded 407 
normally to leptin treatment in terms of food intake and body weight, and to leptin and insulin 408 
(another anorexigenic hormone) in electrophysiological studies [133]. Interestingly, a proportion of 409 
both AGRP/NPY and POMC/CART neurons responded to glucose deprivation by hyperpolarisation 410 
and a consequent reduction in spike frequency, although in neither case was this evident when 411 
AMPK-α2 was knocked out in these neurons. Thus, although AMPK does not appear to be required 412 
for the response to leptin and insulin in these specific (AGRP/NPY or POMC/CART) neurons, it does 413 
seem to be required for glucose-sensing [133]. The latter point is interesting given the evidence that 414 
AMPK can sense glucose in other cells via a non-canonical mechanism [134]. 415 
The apparent lack of effect of knocking out AMPK in AGRP/NPY or POMC/CART neurons on 416 
food intake [133] may be because AMPK is required not in these neurons per se, but in other neurons 417 
acting immediately upstream or downstream. In one study, AGRP/NPY neurons were identified by 418 
their fluorescence in brain slices derived from transgenic mice expressing a fluorescent protein fused 419 
to NPY, and the activity of presynaptic neurons was assessed by measuring miniature excitatory 420 
postsynaptic currents (mEPCs) in these cells, in the presence of tetrodotoxin to suppress firing of 421 
action potentials [135]. Interestingly, treatment of brain slices from fed mice with the orexigenic 422 
hormone ghrelin increased mEPCs in the AGRP/NPY neurons to the level seen in fasted mice. Studies 423 
with pharmacological agents suggested that this was mediated by stimulation of the ghrelin receptor 424 
Ghsr1, which is coupled to intracellular release of Ca2+ via the G protein Gq/G11. This would initiate a 425 
Ca2+-dependent activation of AMPK in the presynaptic neurons via the CaMKK2 pathway. There was 426 
already evidence of CaMKK2 involvement in the response to orexigenic signals, based on studies 427 
using the CaMKK2 inhibitor STO-609 and global mouse knockouts of CaMKK2 [136]. Therefore, 428 
although Yang et al [135] relied heavily on different pharmacological agents, some of which might 429 
have off-target effects, their study provides a plausible model to explain the role of AMPK in feeding 430 
and appetite control in specific neurons of the hypothalamus. One proposal to explain the orexigenic 431 
effects of ghrelin in the hypothalamus, downstream of the CaMKK2-AMPK pathway, involves 432 
reductions in malonyl-CoA levels due to inhibition of acetyl-CoA carboxylase by AMPK, with 433 
consequent activation of carnitine-palmitoyl transferase-1C (CPT1C) [137] and increased levels of 434 
ceramides [138]. 435 
8. AMPK and food choice 436 
The aforementioned findings are all the more intriguing, given recent work [139] which showed 437 
that expression of constitutively active AMPK in hypothalamic PVN neurons led to a preference for 438 
carbohydrate over fat in food choice of mice, through activation by AMPK of CPT1C, which promotes 439 
mitochondrial b-oxidation of fatty acids, within a subset of corticotrophin-releasing hormone-440 
positive neurons in the rostral region of the PVN. It is possible that this affords a coordinating link 441 
between adaptive changes to feeding and food choice and ventilatory oxygen supply, given the 442 
evident reciprocal inputs between PVN and NTS (Fig. 4) that modify peripheral and central 443 
cardiorespiratory reflex responses during hypoxia [140-143]. 444 
 445 
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 446 
Figure 4. When the clock strikes four feed and breathe some more. The diagram shows a tracing of 447 
a sagittal section of a whole mouse brain, indicating anatomical locations where AMPK may regulate 448 
the neural control of appetite/feeding (arcuate nucleus), energy expenditure (ventromedial 449 
hypothalamus) and breathing (NTS + respiratory central pattern generators). 450 
9. Hypothalamic AMPK and energy expenditure through thermogenesis 451 
In another region of the hypothalamus, the ventromedial nucleus (VMH), AMPK appears to be 452 
involved in the regulation of peripheral energy expenditure rather than energy intake, by regulating 453 
the firing of sympathetic nerves that stimulate fatty acid oxidation and hence heat production 454 
(thermogenesis) in brown adipose tissue. Thus, direct administration to VMH by intra-455 
cerebroventricular injection of the female sex hormone estradiol [144], the thyroid hormone T3 [145], 456 
the GLP-1 receptor agonist liraglutide [146] or Bone Morphogenetic Protein-8B (BMP8B) [147,148] all 457 
reduced phosphorylation of AMPK in VMH and increased thermogenesis. In the cases of estradiol 458 
and T3 this was associated with increases in the activity of sympathetic nerves and weight loss. 459 
Moreover, injection of adenoviruses expressing an activated mutant of AMPK reduced the weight 460 
loss associated with either hormone treatment [144,145]. The effects of T3 in VMH were also mediated 461 
in part by stimulation of the vagus nerve to promote lipogenesis in the liver [149]. This effect on 462 
thermogenesis, and hence energy expenditure, appears to be mediated by inhibition of AMPK 463 
complexes containing the α1 isoform in neurons of the VMH expressing Steroidogenic Factor-1 (SF1), 464 
because mice with a specific knockout of AMPK-α1 in these neurons recapitulated the effect of central 465 
T3 [149]. These mice displayed increased thermogenesis and were resistant to diet-induced obesity 466 
[150]. Adding to this, a recent study [151] has highlighted downstream effects of AMPK. Briefly, 467 
chronic genetic activation of AMPK in mice via a D316 mutation in the γ1 subunit was shown to lead 468 
to the emergence, when placed on a high fat but not normal chow diet, of a population of 469 
subcutaneous white adipocytes with small, multilocular lipid droplets. A reduction in body weight 470 
and a decrease in fat mass but not lean mass was observed in these mice when switched to the high 471 
fat diet, alongside improved insulin sensitivity in the absence of any difference in glucose tolerance. 472 
Most interestingly, in the context of the present review, food intake was not significantly different on 473 
the high fat diet, but substantial increases in white adipose tissue oxygen consumption rate were 474 
associated with active thermogenesis. Moreover, while there were no differences in expression of 475 
PPAR-gamma co-activator 1 α (Pgc1α) or components of the mitochondrial electron-transport chain 476 
when these mice were fed a normal chow diet, increased expression of Pgc1α and thus mitochondrial 477 
proteins occurred when they were fed a high fat diet, consistent with browning of white adipocytes. 478 
Note that these findings provide evidence of cell- and context-specific changes in mitochondrial 479 
metabolism, and thus respiratory capacity, consequent to AMPK deficiency, and highlight the 480 
therapeutic potential for the treatment of obesity through increased whole-body energy expenditure. 481 
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Interestingly, while AMPK deficiency in sympathetic (catecholaminergic) neurons might 482 
increase thermogenesis and weight loss, and attenuate HVR, it does not appear to markedly impact 483 
systemic arterial blood pressure regulation during normoxia or hypoxia, which is determined in great 484 
part by increased sympathetic outflow [125]. The only way to reconcile this is if pathways leading to 485 
sympathetic control of thermogenesis differ from those involved in control of blood pressure, which 486 
is perhaps yet another example of cell- and system-specific outputs. 487 
  488 
10. Regulation of oxygen supply, feeding and food choice during adaptive acclimation to hypoxia 489 
at altitude 490 
As one might expect, adaptive thermogenesis is triggered by cold both at sea level and altitude, 491 
and this is partly governed by those sympathetic pathways described above, which will also impact 492 
breathing, feeding and food choice, other than through energy expenditure pathways that may 493 
promote weight loss indirectly (for review see [152]). Moreover, during acclimation to altitude it is 494 
evident that there are differences between acute and chronic adaptive changes to breathing, feeding 495 
and food choice. Intriguingly, longer-term adjustments to ventilatory patterning are accompanied by 496 
changes in food choice, without loss of appetite per se.       497 
It is well recognised that time-dependent augmentation of HVR and thus increased ventilation 498 
accompanies adaptation to altitude [116,153]. In this respect, a recent study has highlighted the role 499 
of carotid body activation and type I cell proliferative responses to sustained hypoxia during 500 
ventilatory acclimatisation, a process which is mediated by HIF-2a, and abrogated by its inhibition 501 
[154]. However, evidence suggests that ventilatory acclimatisation is, at least in part, also determined 502 
by adjustment of NTS afferent inputs to RVLM [155], where regulation of AMPK-α1 expression [110] 503 
and consequent adjustments to AMPK-dependent facilitation of HVR may come in to play [10,115]. 504 
Adding to this, HPV is normally attenuated during sustained chronic hypoxia [156] and acclimation 505 
at altitude [157]. This may serve to oppose the development of chronic hypoxic pulmonary 506 
hypertension, and our data strongly suggest that repression of AMPK-α1 expression may be relevant 507 
here too [50]. This draws us back once again to the SNPs identified in PRKAA1 of Andean populations 508 
that have adapted to life under relative hypoxia at altitude [95]. Intriguingly, this ethnic group enter 509 
relative hypoventilation during exercise at altitude [96], and exhibit attenuated HPV with postnatal 510 
persistence of pulmonary hypertension [96]. In short, it seems plausible that cardiorespiratory 511 
acclimitisation to hypoxia at altitude may be driven by cell-specific changes in AMPK subunit 512 
expression and/or AMPK activity, which is generally considered to be governed independently of 513 
HIF1-a or HIF2-a. However, it is noteworthy that those signalling pathways regulated by AMPK and 514 
HIF1/2-a may indirectly influence each other in a cell-specific manner, delivering both opposing and 515 
cooperative outcomes depending on the context. For example, activation of either AMPK or HIF may 516 
increase glucose uptake, glycolytic flux and autophagy, and suppress protein translation. However, 517 
where mitochondrial biogenesis is concerned they oppose each other, AMPK promoting 518 
mitochondrial biogenesis while, by contrast, HIF signalling under prolonged hypoxia generally acts 519 
to decrease mitochondrial mass (for detailed review see [158]). Therefore, AMPK and HIF may, each 520 
in part, deliver appropriate adjustments to whole-body metabolism in a cell- and thus system-specific 521 
manner. 522 
Adding to this, a growing body of evidence suggests that during the process of adaptive 523 
acclimation, neuroendocrine systems that contribute to the control of feeding respond differentially 524 
to acute hypoxia and chronic hypoxia. Moreover, we know chemoreflex pathways that govern 525 
ventilation are not restricted to the medulla and pons, but extend to the mesencephalic and 526 
hypothalamic regions, and in doing so confer developmentally regulated relays between caudal and 527 
ventral hypothalamic neurons that control feeding and thermogenesis, and those medullary neurons 528 
involved in central afferent input responses to hypoxia  [159-161]. Reciprocal inputs also project from 529 
the PVN to the NTS, and may contribute to the modulation of NTS neuronal activation, chemoreflex 530 
input responses and thus cardiorespiratory control during hypoxia [140-143,162].  531 
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This role of the PVN in supporting arterial oxygen supply by modulating respiratory responses 532 
to hypoxia through the NTS [142,143] and the reciprocal innervation between the NTS and PVN, 533 
highlights the possibility that feeding and the efficiency of energy utilisation by the body may rely 534 
on similar levels of reciprocity [163]. This may be achieved, at least in part, through the influence of 535 
these pathways on not only feeding, but also food choice during hypoxia when oxygen availability 536 
declines at altitude [164], and perhaps, therefore, when oxygen intake and utilisation by the body 537 
falls with age and disease. Supporting this, it has been noted that upon ascent to altitude plasma 538 
levels of the “satiety hormone” leptin may increase immediately, followed by delayed falls in the 539 
“hunger hormone” ghrelin; it is also interesting to note in this regard that gestational hypoxia can 540 
disrupt the neonatal leptin surge in such a way that hyperphagia and obesity are programmed for 541 
adult life [165].  Moreover, during ascent of adults to altitude this leptin surge is accompanied by a 542 
delayed increase in NPY levels, and decreased POMC in the arcuate nucleus after seven days at 543 
altitude [166,167], and this too may be critical to the regulation of feeding behaviour during 544 
acclimation. In these respects, however, the possible role of AMPK remains to be explored. 545 
It is nevertheless notable that when humans that dwell at sea level are acutely exposed to 546 
hypoxia, they exhibit increased anaerobic glucose metabolism [168]. Moreover, after acclimation at 547 
altitude (4,300 m) muscle fatty acid consumption decreases during rest and exercise, while glucose 548 
uptake increases during exercise [169]. This switch to carbohydrates, and reduced reliance on lactate, 549 
occurs after 3 weeks of altitude acclimatisation in males [170,171], and likely persists in long-term 550 
high-altitude residents [172]. The reasons for this seem clear, because use of carbohydrates (glucose, 551 
glycogen) as fuel, rather than free fatty acids or other lipids, can generate 25–50% more ATP per mole 552 
of oxygen consumed [173]. Accordingly, a high carbohydrate diet has been reported to increase 553 
endurance for heavy work at altitude, and also ameliorates symptoms of acute mountain sickness 554 
[174].   555 
The possibility of coordinate regulation of breathing, feeding and food choice is all the more 556 
intriguing in this context, when one considers that this metabolic shift to carbohydrates is evident not 557 
only in newcomers acclimatised to altitude, but also in adapted Andeans, Tibetans and Sherpa (for 558 
review see [172,175]), and is associated with less sympathetic and/or greater parasympathetic 559 
stimulation [176-178]. Moreover, even after descent to sea level altitude-adapted Andean (Quechua) 560 
and Sherpa males exhibit a greater reliance on carbohydrate metabolism and a 50–60% gain in the 561 
production of ATP per mole of oxygen consumption relative to lowlanders, which persists during 562 
acute hypoxia and moderate exercise [179]. The possible role of PRKAA1 expression in these 563 
processes remains to be determined in either lowlanders or Andeans. However, in adapted Tibetans, 564 
who exhibit no identified SNPs in PRKAA1, it has been established that lactate levels are positively 565 
associated with an adaptive EPAS1 (HIF1a) haplotype (and perhaps EGLN1 which encodes prolyl 566 
hydroxylase domain-containing protein 2 (PHD2)) which is consistent with decreased glucose 567 
oxidation, while changes to serum free fatty acids are associated with a PPARA haplotype (PPARA 568 
encodes the nuclear receptor protein PPARα, a regulator of fatty acid oxidation [180]).  569 
11. Pathological links between AMPK, oxygen supply and food choice  570 
In the context of disorders related to feeding and food choice among lowlanders we gain further 571 
traction, and further evidence of reciprocity with respect to respiratory control mechanisms. 572 
Pulmonary hypertension and sleep-disordered breathing are not only symptomatic of altitude 573 
sickness [153,181,182], but also of metabolic disease [106,183-186], with which cell-specific alterations 574 
in AMPK subunit expression patterns are known to occur [187,188]. Adding to this, inverse 575 
relationships between residence at altitude and the risk of diabetes [178] and obesity [189] have been 576 
noted. This has been attributed to the association between chronic hypoxia at high altitude and 577 
decreased serum glucose and insulin concentrations in humans [190,191]. Consistent with this, 578 
Tibetan highlanders have a relatively low prevalence of diabetes [192], although they also have a 579 
relatively low-calorie diet [193], and relatively low body weight [194]. 580 
It seems equally plausible, therefore, that AMPK isoform expression might be affected by 581 
gestational hypoxia or chronic intermittent hypoxia in adults. Aberrant, cell-specific changes to 582 
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AMPK isoform expression patterns could thereby be triggered and contribute to the onset of obesity, 583 
type 2 diabetes [165,195,196], and sleep-disordered breathing [105,116] in later life.  This possibility 584 
gains indirect support from our studies, because AMPK deletion in catecholaminergic cells not only 585 
attenuates HVR, but also confers a neonate-like HVR characterised by delayed hypoventilation and 586 
apnoea in adults exposed to hypoxia, but with preservation of hypoxic-hypercapnic ventilatory 587 
responses. In short, these mice exhibit HVR similar to that of pre-term infants that are susceptible to 588 
sudden infant death syndrome [110,197]. In short, AMPK may be necessary in some as yet 589 
unrecognised way for appropriate maturational shifts from neonatal to adult HVR patterning [116]. 590 
Supporting this, neonatal exposure to poikilocapnic intermittent hypoxia precipitates sleep-591 
disordered breathing in later life, in part through consequential, life-long depression of HVR [116]. 592 
Moreover, as mentioned above, gestational hypoxia disrupts the neonatal leptin surge in such a way 593 
that hyperphagia and obesity are programmed for adult life [165]. 594 
When considering pulmonary hypertension, however, we meet a paradox. AMPK facilitates 595 
HPV and thus acute hypoxic pulmonary hypertension, yet appears to oppose chronic hypoxic 596 
pulmonary hypertension [42,198,199]. This is logical, because hypoxic pulmonary hypertension is 597 
considered to be a proliferative disease, which would be opposed by activation of the AMPK-ULK1-598 
mTORC1 pathway, through induction of autophagy [200], and inhibition of lipid, protein and rRNA 599 
biosynthesis [201]. Accordingly, AMPK activation using metformin [202] may ameliorate chronic 600 
hypoxic pulmonary hypertension [203], although significant AMPK-independent actions of 601 
metformin might impact cell metabolism and function here [204,205].  Adding to this, it has been 602 
suggested that pulmonary arteries from human patients with idiopathic pulmonary hypertension 603 
exhibit AMPK deficiency [42,199]. If this is the case, then the progression of pulmonary hypertension, 604 
whether idiopathic or hypoxic, must be driven in some way through cell- and system-specific 605 
repression of AMPK expression. Given that HPV is facilitated by AMPK [50], this could partly explain 606 
why HPV is attenuated during chronic hypoxia [156] and acclimation at altitude [157], should 607 
progression from acute to chronic hypoxic pulmonary hypertension result from excessive repression 608 
of AMPK expression in the pulmonary vasculature during sustained chronic hypoxia. If this proves 609 
to be the case, then AMPK repression could also contribute to idiopathic neonatal pulmonary 610 
hypertension, a hypertensive vasculopathy exclusive to the pulmonary vasculature of children that 611 
is triggered by brief post-natal exposure to hypoxia and maternal metabolic inputs in utero [6,206,207].  612 
These possibilities again receive indirect support from studies on Andeans if, as suspected, 613 
cell-specific AMPK-α1 repression is delivered through identified SNPs in PRKAA1 [95], because 614 
Andeans not only enter relative hypoventilation during exercise at altitude [96], but also exhibit 615 
attenuated HPV with postnatal persistence of pulmonary hypertension [96]. Adding to this, it is 616 
evident that some animals that ordinarily live at and are adapted to high altitude, such as Guinea-617 
pigs, exhibit markedly attenuated HPV [208] and HVR [209], yet retain, albeit to lesser degrees, the 618 
capacity for remodelling within the pulmonary vasculature [208,210] and brainstem [211,212] during 619 
sustained chronic and chronic intermittent hypoxia.  620 
When considering metabolic and respiratory disease in the context of oxygen supply at altitude, 621 
it is of further intrigue to note that while there is evidence of increased susceptibility to some 622 
infections at high altitude [213], those living at and adapted to high altitude (Andeans and Tibetans) 623 
may be less likely to develop severe adverse respiratory dysfunction during other infections, such as 624 
SARS-CoV-2 (COVID-19) [214]. Given that the  innate and adaptive immune responses are subject to 625 
modulation by hypoxia [215], it is significant that they can be modulated by AMPK, in addition to 626 
HIFs-a, in either a beneficial or detrimental way depending on the nature of infection [216]. 627 
Supporting this, certain RNA and DNA viruses may trigger time-dependent reductions and/or 628 
increases in AMPK activity to facilitate viral entry, adjust cellular metabolism in order to facilitate 629 
replication, and to combat innate host cell immunity [217]. By contrast, AMPK may oppose bacterial 630 
infection through induction of autophagy/xenophagy [217,218]. Interestingly, there is also emerging 631 
evidence of a link between adaptation of ventilatory control mechanisms during chronic intermittent 632 
hypoxia [211,219], sleep-disordered breathing [220-222] and homeostatic changes to the gut 633 
microbiota, i.e. those symbiotic bacteria that provide the human host with nutrients, facilitate 634 
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digestion and prevent colonisation of the gut by subversive, opportunistic pathogens [223]. Of 635 
relevance here may be the fact that the intestinal microbiota and its metabolites modulate autophagy 636 
through the mTOR pathway, while AMPK, a key regulator of autophagy, has been shown to be 637 
activated in the liver, skeletal muscle and colon of germ-free mice [224]. 638 
12. Clinical Perspective 639 
From the evidence presented above it is clear that AMPK contributes to relevant peripheral and 640 
central regulatory mechanisms governing oxygen supply and availability, which may impact upon 641 
feeding, food choice and weight gain, and vice versa, through our motivation to breathe and/or select 642 
particular nutrients. It is also evident that high-altitude adaptation may ameliorate the risk of obesity 643 
and diabetes. This raises the possibility that the selection of particular nutrients may not only lead to 644 
obesity, but also reduce oxygen demand and thus ventilatory supply, which could in turn lead to 645 
sleep-disordered breathing and pulmonary hypertension, in a manner exacerbated through 646 
consequent changes in cell-specific expression of AMPK subunit isoforms. Because our 647 
understanding of the mechanisms by which AMPK affects cardiorespiratory control and feeding is 648 
rudimentary, further research should therefore be encouraged. This may reveal new therapeutic 649 
strategies, through modulation of the activities and/or expression of AMPK or its downstream 650 
targets. In the context of pulmonary hypertension and sleep-disordered breathing of newborns and 651 
adults, the mechanisms are largely unknown, current therapies poor, and the unmet clinical need is 652 
clear from the following statistics: 653 
• idiopathic neonatal pulmonary hypertension affects 60 per million, with 50-75% survival at 654 
5 years [225];  655 
• idiopathic pulmonary hypertension of adults affects ≈15 per million [226], where life-656 
expectancy is ≤6 years [226]; 657 
• sudden infant death syndrome, which has been linked to hypoventilation and apnoea of pre-658 
term infants during hypoxia [197], is the leading cause of death in otherwise healthy infants, 659 
and currently accounts for approximately 300 deaths per annum in the UK (UK Office for 660 
National Statistics),  and 2000 deaths per annum in the USA [227];   661 
• sleep-disordered breathing [105] affects 3-5 million in the UK (UK Office for National 662 
Statistics), 15-65 million in the USA [228], and is associated with all-cause mortality [196]; 663 
• acute respiratory distress syndrome  is associated with pulmonary hypertension [229,230], 664 
obesity and sleep-disordered breathing [231], may be opposed by AMPK [232], and is 665 
triggered by SARS, MERS [233] and COVD-19 [234]. 666 
 667 
There will likely be as yet unforeseen therapeutic potential, given that adult neuroendocrine 668 
responses to critical illness alter breathing and feeding behaviour with either beneficial or deleterious 669 
effect, depending on individual circumstance [164,235]. In this respects one final alluring fact is that 670 
previous periods of exposure to hypoxia at altitude (>8000 metres) provide up to eight weeks 671 
protection against acute mountain sickness [236], the occurrence of which is slightly higher in the 672 
obese and those with underlying lung disease, and lower in those that, irrespective of fitness, breathe 673 
more [237].  674 
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